These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17229142)

  • 1. Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1.
    Lodderstedt G; Hess S; Hause G; Scheuermann T; Scheibel T; Schwarz E
    FEBS J; 2007 Jan; 274(2):346-55. PubMed ID: 17229142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
    Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
    Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trinucleotide expansions leading to an extended poly-L-alanine segment in the poly (A) binding protein PABPN1 cause fibril formation.
    Scheuermann T; Schulz B; Blume A; Wahle E; Rudolph R; Schwarz E
    Protein Sci; 2003 Dec; 12(12):2685-92. PubMed ID: 14627730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hofmeister salts and potential therapeutic compounds accelerate in vitro fibril formation of the N-terminal domain of PABPN1 containing a disease-causing alanine extension.
    Lodderstedt G; Sachs R; Faust J; Bordusa F; Kühn U; Golbik R; Kerth A; Wahle E; Balbach J; Schwarz E
    Biochemistry; 2008 Feb; 47(7):2181-9. PubMed ID: 18205394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring fibril formation of the N-terminal domain of PABPN1 carrying an alanine repeat by tryptophan fluorescence and real-time NMR.
    Rohrberg J; Sachs R; Lodderstedt G; Sackewitz M; Balbach J; Schwarz E
    FEBS Lett; 2008 May; 582(11):1587-92. PubMed ID: 18406354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
    Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
    Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and dynamical characterization of fibrils from a disease-associated alanine expansion domain using proteolysis and solid-state NMR spectroscopy.
    Sackewitz M; Scheidt HA; Lodderstedt G; Schierhorn A; Schwarz E; Huster D
    J Am Chem Soc; 2008 Jun; 130(23):7172-3. PubMed ID: 18481858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dynamism of PABPN1 nuclear inclusions during the cell cycle.
    Marie-Josée Sasseville A; Caron AW; Bourget L; Klein AF; Dicaire MJ; Rouleau GA; Massie B; Langelier Y; Brais B
    Neurobiol Dis; 2006 Sep; 23(3):621-9. PubMed ID: 16860991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oculopharyngeal muscular dystrophy: study of patients from seven Spanish families with different GCG expansions in PABP2 gene].
    Pou Serradell A; Lloreta Trull J; Corominas Torres JM; Hammouda EH; Urtizberea JA; Richard P; Brais B
    Neurologia; 2004 Jun; 19(5):239-47. PubMed ID: 15150706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The unresolved puzzle why alanine extensions cause disease.
    Winter R; Liebold J; Schwarz E
    Biol Chem; 2013 Aug; 394(8):951-63. PubMed ID: 23612654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.
    Rivera D; Mejia-Lopez H; Pompa-Mera EN; Villanueva-Mendoza C; Nava-Castañeda A; Garnica-Hayashi L; Cuevas-Covarrubias S; Zenteno JC
    Br J Ophthalmol; 2008 Jul; 92(7):998-1002. PubMed ID: 18577654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly-(L-alanine) expansions form core beta-sheets that nucleate amyloid assembly.
    Shinchuk LM; Sharma D; Blondelle SE; Reixach N; Inouye H; Kirschner DA
    Proteins; 2005 Nov; 61(3):579-89. PubMed ID: 16114037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice.
    Dion P; Shanmugam V; Gaspar C; Messaed C; Meijer I; Toulouse A; Laganiere J; Roussel J; Rochefort D; Laganiere S; Allen C; Karpati G; Bouchard JP; Brais B; Rouleau GA
    Neurobiol Dis; 2005 Apr; 18(3):528-36. PubMed ID: 15755680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
    Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
    Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational stability of the RNP domain controls fibril formation of PABPN1.
    Liebold J; Winter R; Golbik R; Hause G; Parthier C; Schwarz E
    Protein Sci; 2015 Nov; 24(11):1789-99. PubMed ID: 26267866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy.
    Gürtler N; Plasilova M; Podvinec M; Boesch N; Müller H; Heinimann K
    Laryngoscope; 2006 Jan; 116(1):111-4. PubMed ID: 16481821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
    Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
    J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyalanine-independent conformational conversion of nuclear poly(A)-binding protein 1 (PABPN1).
    Winter R; Kühn U; Hause G; Schwarz E
    J Biol Chem; 2012 Jun; 287(27):22662-71. PubMed ID: 22570486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
    Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
    Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
    Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
    Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.